Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Meeting Resources
  3. European Lung Cancer Congress 2023

Genotyping in NSCLC: Monitoring, germline alterations, minimal residual disease

Value of genotyping in the assessment of minimum residual disease

Date

31 Mar 2023

Session

Genotyping in NSCLC: Monitoring, germline alterations, minimal residual disease

Topics

Tumour Site

Non-Small Cell Lung Cancer

Presenters

Luis Paz-Ares

Authors

L. Paz-Ares

Author affiliations

  • Hospital Universitario 12 de Octubre, Madrid/ES

Resources

This content is available to ESMO members and event participants.
Login

Resources from the same session

Q&A

Presenter: Anne-Marie Baird

Session: Genotyping in NSCLC: Monitoring, germline alterations, minimal residual disease

Resources:

Webcast

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.